arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

PLIANT THERAPEUTICS, INC.

PLRX

$1.06 ▲ +0.02 (+1.91%) at close

8 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Moderately Bearish

auto_awesome

Analytical Summary

PLIANT THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $65.0M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -68.2% ↘

FCF / Share $-2.10 ↗

Trailing P/E —

Price / Book 0.4x

FCF Yield —

Debt / Equity 0.00

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-149.34M

↑ +29.0% —

Operating Margin Operating profit as % of sales

-99.6%

↓ -4515.5% —

FCF / Share Free cash flow per share

$-2.10

↑ +20.3% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↑

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2018

FY 2019

$0.00

FY 2020

FY 2021

$0.00

FY 2022

$0.00

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	—	N/M	-83.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1146%)	27.9% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+249%)	-81.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1124%)	-26.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-434%)	—	—
EPS Growth YoY (%)	30.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-26.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	6.5% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-8.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-39.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	53.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	29.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-30.4% Weak ↑ Weak Improving Year-over-year change in net income	-30.8% Weak ↑ Weak Improving Year-over-year change in net income	-26.8% Weak ↑ Weak Improving Year-over-year change in net income	-134.2% Weak Weak Year-over-year change in net income	-6482.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	20.3% Good ↑ Good Improving Year-over-year change in free cash flow	-31.8% Weak ↓ Weak Declining Year-over-year change in free cash flow	12.9% Fair ↑ Fair Improving Year-over-year change in free cash flow	-6.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	-18.8% Weak Weak Year-over-year change in free cash flow	20.5% Good Good Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	—	—	-66.4% Weak Weak Compound annual revenue growth over 3 years	-44.6% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	-99.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-764%)	-2.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-114%)	—
Profit Margin (%) (%)	—	—	—	—	—	-99.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-928%)	-1.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-109%)	—
FCF Margin (%) (%)	—	—	—	—	—	-92.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-6.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	5.89x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-68.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-54.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-30.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	1.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-69.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-57.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-14.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-1.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-82.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-649%)	-69.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-561%)	-34.1% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-327%)	-39.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-362%)	-48.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-426%)	-14.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-198%)	0.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-94%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Debt to Equity (x)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.10x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-83%)	0.02x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-96%)	0.03x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-95%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—
Interest Coverage (x)	-61.59x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-87.16x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-145.34x Weak Weak Operating income divided by interest expense Optimal: > 5x	-206.83x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-45.45M	$-40.98M	$-53.18M	$-23.76M	$-51.66M	$-50.88M	$-85.81M	—
Debt / EBITDA (x)	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.13x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.06x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.08x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 8 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.03	$0.23	$0.21	$1.96	$35.14	—
Basic EPS, GAAP (USD)	$-2.43	$-3.47	$-2.75	$-2.94	$-2.71	$-1.95	$-4.22	—
Free Cash Flow per Share (USD)	$-2.10	$-2.63	$-2.00	$-2.29	$-2.16	$-1.82	$-2.29	—
Dividend per Share (USD)	$0.00	$0.00	$0.00	$0.00	—	$0.00	—	—
Book Value per Share (USD)	$2.95	$5.00	$7.90	$6.40	$5.52	$7.96	$-41.33	—
Tangible Book Value per Share (USD)	$2.95	$5.00	$7.90	$6.40	$5.52	$7.96	$-41.33	—
Basic Weighted Avg Shares (shares)	61.37M	60.54M	58.72M	42.02M	35.85M	21.34M	1.62M	—
Dividend Payout Ratio (%)	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$180.08M	$329.05M	$476.98M	$316.40M	$192.61M	$279.15M	$103.73M	—
LT Debt (USD)	$0.00	$30.21M	$10.05M	$9.93M	$0.00	—	—	—
Total Equity (USD)	$181.21M	$304.08M	$473.58M	$313.34M	$199.06M	$283.06M	$-76.30M	$-71.47M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$1.58M	$9.69M	$7.57M	$41.82M	$57.05M	—
Depreciation Expense (USD)	$1.70M	$2.12M	$1.84M	$1.82M	$1.53M	$1.31M	$1.11M	—
Net Income, GAAP (USD)	$-149.34M	$-210.30M	$-161.34M	$-123.32M	$-97.26M	$-41.53M	$-631.00K	—
Operating Cash Flow (USD)	$-128.34M	$-155.50M	$-116.36M	$-94.63M	$-75.44M	$-37.27M	$-2.75M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters

PLIANT THERAPEUTICS, INC.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PLRX with peers